IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a one-year, multi-center study demonstrates the safety and durability of its proprietary MicroPulse technology as a treatment for glaucoma. The educational symposium was led by Drs. Ike Ahmed, David Gossage, and Elias Reichel and was attended by more than 300 ophthalmologists during the American Society of Cataract and Refractive Surgeons (ASCRS) conference in April.
"The one-year results showed a sustained intra-ocular pressure (IOP) decrease of 20-25%," reported Dr. Ahmed, a glaucoma specialist, based on data he calculated along with Drs. Nathan Radcliffe, Steven Vold and David Gossage. "This multi-center study provides evidence that pressure lowering with MicroPulse Laser Trabeculoplasty is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven't seen significant effects from medications."
Will Moore, CEO of IRIDEX commented, "Prior studies have substantiated the safety, efficacy, and durability of MicroPulse for treating various retinal diseases caused by diabetes." Moore continued, "With the addition of this data for glaucoma, we believe the versatility of our MicroPulse laser systems are ideally suited to the broader global market of comprehensive ophthalmologists."
The complete video recording of the symposium will be published on the IRIDEX website (www.iridex.com) once available.